Psy19 a Cost Per Responder Analysis of Secukinumab Compared to Other Biologics for Treatment of Moderate to Severe Psoriasis Patients Over 1 Year in Morocco

Abstract

The risk of discontinuation from oxycodone treatment was nearly double the risk of tapentadol (32.6% versus 16.3%). Considering the costs associated with AEs and opioid switches, higher daily treatment costs with tapentadol were totally offset, leading to cost savings with tapentadol (NHS-P: V226.05 versus V237.22; S-P: V465.78 versus V470.80). Conclusions: Despite higher drug costs compared to generic oxycodone, tapentadol's better tolerability and the associated lower risk of treatment discontinuation results in cost-savings during the first month, thereby allowing the physician to individually assess the appropriateness of tapentadol treatment without increasing total costs for the NHS or society.